Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2006; 12(30): 4888-4891
Published online Aug 14, 2006. doi: 10.3748/wjg.v12.i30.4888
Published online Aug 14, 2006. doi: 10.3748/wjg.v12.i30.4888
Table 1 Demographic and clinical data of patients who completed the treatment
| Group A(Triple therapy) | Group B(Quadrupletherapy) | Group C(New protocol) | |
| Patients (n) | 110 | 113 | 112 |
| Male, n (%) | 57 (52 ) | 60 (53 ) | 62 (55 ) |
| Female, n (%) | 53 (47 ) | 53 (47 ) | 50 (45 ) |
| Age range (yr) | 28-79 (median 41) | 24-47 (median 39) | 31-68 (median 47) |
| Minor side effects, n (%) | 6 (5) | 5 (4) | 12 (11) |
| Overall eradication (n) | 101 | 97 | 104 |
| Intention-to-treat (%) | 84.17 | 80.83 | 86.67 |
| Per-protocol (%) | 91.81 | 85.84 | 92.85 |
- Citation: Mirbagheri SA, Hasibi M, Abouzari M, Rashidi A. Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H pylori eradication: A comparative three-armed randomized clinical trial. World J Gastroenterol 2006; 12(30): 4888-4891
- URL: https://www.wjgnet.com/1007-9327/full/v12/i30/4888.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i30.4888